CN111000908A

CN111000908A - Application of herba Gei Piloselloidis extract in preparing medicine for preventing and treating autoimmune disease

Info

Publication number: CN111000908A
Application number: CN201911381591.0A
Authority: CN
Inventors: 李明
Original assignee: Lvyuan Qiuzheng Technology Development Co Ltd
Current assignee: Lvyuan Qiuzheng Technology Development Co Ltd
Priority date: 2019-12-27
Filing date: 2019-12-27
Publication date: 2020-04-14

Abstract

The invention discloses an application of a herba Gei extract in preparing a medicine for preventing and treating autoimmune diseases, and belongs to the technical field of medicines. The preparation method of the herba Gei extract comprises the following steps: soaking and extracting the blue cloth in first alcohol, adding water, and continuously soaking and extracting to obtain an alcohol extract; concentrating the ethanol extractive solution under reduced pressure, and spray drying to obtain solid powder; dissolving the solid powder in water, extracting with ethyl acetate, removing ethyl acetate extract, and extracting with second alcohol to obtain alcohol extract; drying the alcohol extract under reduced pressure, and sequentially freeze-drying and grinding to obtain the product. The herba Gei Piloselloidis extract has remarkable preventing and treating effects on autoimmune diseases such as ulcerative colitis, regional enteritis, proctitis, bacillary dysentery, enteritis, gastric ulcer, rheumatoid arthritis, etc.

Description

Application of herba Gei Piloselloidis extract in preparing medicine for preventing and treating autoimmune disease

Technical Field

The invention relates to the technical field of medicines, in particular to application of a herba Gei extract in preparing a medicine for preventing and treating autoimmune diseases.

Background

Ulcerative colitis is a common inflammatory process in the 20-30 years old, limited to the colonic mucosa and submucosa. Lesions are mostly located in the sigmoid colon and rectum, and may extend to the descending colon, or even the entire colon. The pathology is long and often attacks repeatedly. The intestinal mucosa is diffuse inflammation, normal mucosa can not be basically seen, the intestinal mucosa is in continuous lesion, and the inherent muscular layer of the intestinal wall is not obviously affected. The ulcer is generally not deep and does not cause perforation, fistula or stenosis, obstruction. The disease is unknown, but is thought to be associated with genetic factors (susceptibility to certain families), immune dysfunction (autoimmune disease), infection, mental factors, and the like. Ulcerative colitis has no specific method, but can control the continued development of inflammation by inhibiting the immune system of the body through salicylic acids, glucocorticoid medicaments and immunosuppressants. Two basic goals of treatment are to relieve clinical symptoms and to maintain an asymptomatic state. Surgical treatment may be desirable when medical drug treatment is ineffective.

Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by arthromeningitis. The clinical symptoms are morning stiffness, symmetric joint swelling and pain (metacarpophalangeal joints, wrist joints, shoulder joints, interphalangeal joints, ankle joints and knee joints), rheumatoid nodules, rheumatoid vasculitis, rheumatoid heart disease, rheumatoid lung diseases, kidney damage, keratitis, sicca syndrome, digestive tract damage, Felty syndrome, Raynaud's phenomenon and the like. Synovitis in joints persists repeatedly and can lead to cartilage and bone destruction in joints, joint dysfunction, and even disability. Vasculitis affects all organs of the body. The rheumatoid arthritis has no specific treatment until now and remains in the treatment of inflammation and sequelae. Current treatments aim to control inflammation of joints and other tissues, relieving symptoms; maintaining joint function and preventing deformity; repairing damaged joints to relieve pain and restore function, etc. The etiology of rheumatoid arthritis is unknown and is thought to be associated with infection by infectious agents such as epstein-barr virus or streptococcal autoimmune disease. Approximately 65% to 93% of patients with rheumatoid arthritis have EB virus core antibodies in their sera. The disease is more prevalent in certain families. To date, there has been no specific effective treatment for this disease. The commonly used symptomatic treatment medicines mainly comprise: salicylates, nonsteroidal anti-inflammatory drugs, corticosteroids, penicillamine, immunosuppressants, and the like. For those who cannot be treated with the medicine, some patients can also be treated by operation.

Although significant advances have been made in the prevention and treatment of these diseases associated with autoimmune diseases. However, the number of people suffering from various autoimmune diseases and the above-mentioned disease infestations remains surprisingly high. Moreover, the currently available treatment regimens, drugs and methods are essentially supportive and symptomatic treatments that do not provide treatments that can ameliorate pathological conditions. Therefore, research and development of effective new therapeutic strategies for autoimmune diseases such as ulcerative colon and rheumatoid arthritis are indispensable.

Disclosure of Invention

The embodiment of the invention aims to provide application of a herba cynanchi bungei extract in preparing a medicament for preventing and treating autoimmune diseases so as to solve the problems in the background technology.

In order to achieve the above purpose, the embodiments of the present invention provide the following technical solutions:

an application of herba Gei extract in preparing medicine for preventing and treating autoimmune diseases is disclosed, wherein the active ingredients of the herba Gei extract comprise polysaccharide compound and tannin compound; the mass content of the polysaccharide compound is 35-55%, and the mass content of the tannin compound is 20-40%.

As a preferred aspect of the embodiments of the present invention, the autoimmune disease is one or more of ulcerative colitis, regional enteritis, bacillary dysentery, proctitis, enteritis, gastric ulcer, and rheumatoid arthritis.

As another preferred embodiment of the present invention, the autoimmune disease is ulcerative colitis and/or rheumatoid arthritis.

As another preferable aspect of the embodiment of the present invention, the preparation method of the cervus elaphus linnaeus extract comprises the steps of:

soaking and extracting the blue cloth in first alcohol, adding water, and continuously soaking and extracting to obtain an alcohol extract;

concentrating the ethanol extractive solution under reduced pressure, and spray drying to obtain solid powder;

dissolving the solid powder in water, extracting with ethyl acetate, removing ethyl acetate extract, and extracting with second alcohol to obtain alcohol extract;

and (3) drying the alcohol extract under reduced pressure, and then sequentially carrying out freeze drying treatment and grinding treatment to obtain the blue cloth extract.

In another preferable scheme of the embodiment of the invention, in the step of obtaining the alcohol extract, after the blue cloth is placed in the first alcohol for soaking extraction, water is added for further soaking extraction, and the mass volume ratio of the blue cloth to the first alcohol is 1 (2-4) in kg/L; the volume ratio of the first alcohol to the water is 1 (0.5-1.5).

In another preferred embodiment of the present invention, the first alcohol and the second alcohol are each independently a C1-C4 alcohol.

As another preferable aspect of the embodiment of the present invention, the first alcohol is ethanol; the second alcohol is n-butanol.

In another preferred embodiment of the present invention, the step of subjecting the alcohol extract to concentration under reduced pressure and then to spray drying to obtain a solid powder comprises subjecting the alcohol extract to concentration under reduced pressure at a temperature of 40 to 60 ℃.

As another preferable scheme of the embodiment of the present invention, in the step of obtaining the bluecloth normal extract by performing the vacuum drying treatment on the alcohol extract, and then sequentially performing the freeze-drying treatment and the grinding treatment, the temperature of the vacuum drying treatment is 40 to 60 ℃.

As another preferable mode of the embodiment of the present invention, in the step of obtaining the bluecloth extract by performing the vacuum drying treatment on the alcohol extract, and then sequentially performing the freeze-drying treatment and the grinding treatment, the temperature of the freeze-drying treatment is-80 to-70 ℃.

Compared with the prior art, the embodiment of the invention has the beneficial effects that:

the active ingredients such as tannin compounds in the extract of the euonymus alatus prepared by the embodiment of the invention can treat bacterial infection and autoimmune disease. Particularly, the pharmaceutical composition has remarkable prevention and treatment effects on diseases or disease states such as ulcerative colitis, regional enteritis (Crohn's disease), proctitis, bacillary dysentery, enteritis, gastric ulcer and rheumatoid arthritis, and the effects comprise the protection effect on colon and rectal mucosa and submucosal tissues and structures, the repair and structural reconstruction of damaged colon mucosa, rectal mucosa and joint capsule tissues, joint cartilage microarchitecture caused by the ulcerative colitis, the regional enteritis (Crohn's disease), the proctitis, the bacillary dysentery, the enteritis, the gastric ulcer and the rheumatoid arthritis are stimulated, and the function of damaged organs and tissues is helped to be restored.

Drawings

FIG. 1 is a reverse phase chromatography chromatogram of the positive blue-cloth extract obtained in example 3.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1

This embodiment provides a method for preparing a aleppo avens extract, which comprises the steps of:

(1) in 7 months, blue cloth is collected from Guizhou province of China, and ventilation and shade drying treatment is carried out on the blue cloth for later use.

(2) Soaking 50kg of the treated blue cloth in 100L of methanol for 6h, adding 50L of water, soaking for 6h, repeating the above steps for 2 times, and mixing extractive solutions to obtain alcoholic extractive solution.

(3) And (3) placing the alcohol extract at the temperature of 40 ℃ for constant-temperature reduced-pressure concentration treatment, and then performing spray drying treatment to obtain solid powder.

(4) Dissolving the solid powder in 50L of water, extracting with 100L of ethyl acetate, removing ethyl acetate extract, and extracting with 50L of n-propanol to obtain alcohol extract.

(5) Drying the above alcohol extractive solution at 40 deg.C under reduced pressure to obtain jelly, dissolving the jelly with a small amount of water, placing in-70 deg.C refrigerator overnight, freeze drying, taking out, and grinding to obtain herba Gei Piloselloidis extract.

Example 2

(2) Soaking 50kg of the treated blue cloth in 200L of n-propanol for 6h, adding 300L of water, soaking for 6h, repeating the above steps for 3 times, and mixing extractive solutions to obtain alcoholic extractive solution.

(3) And (3) placing the alcohol extract at the temperature of 60 ℃ for constant-temperature reduced-pressure concentration treatment, and then performing spray drying treatment to obtain solid powder.

(4) Dissolving the solid powder in 50L water, extracting with 100L ethyl acetate, removing ethyl acetate extract, and extracting with 50L n-butanol to obtain alcohol extract.

(5) Drying the above alcohol extractive solution at 60 deg.C under reduced pressure to obtain jelly, dissolving the jelly with a small amount of water, placing in-75 deg.C refrigerator overnight, freeze drying, taking out, and grinding to obtain herba Gei Piloselloidis extract.

Example 3

(2) Soaking 50kg of the treated blue cloth in 150L ethanol for 6h, adding 150L water, soaking for 6h, repeating the above steps for 3 times, and mixing extractive solutions to obtain alcoholic extractive solution.

(3) And (3) placing the alcohol extract at the temperature of 50 ℃ for constant-temperature reduced-pressure concentration treatment, and then performing spray drying treatment to obtain solid powder.

(5) Drying the above alcohol extractive solution at 50 deg.C under reduced pressure to obtain jelly, dissolving the jelly with a small amount of water, placing in-80 deg.C refrigerator overnight, freeze drying, taking out, and grinding to obtain herba Gei Piloselloidis extract.

Experimental example:

first, the euonymus japonicus extract obtained in example 3 was subjected to reverse phase chromatography using agilent high pressure liquid chromatography and reverse phase column chromatography, and the chromatogram obtained was as shown in fig. 1. As can be seen from the figure, the extract of herba Gei aleppici mainly contains three major components:

water-insoluble matter: the active site powder is dissolved in water, filtered or centrifuged to obtain a precipitate, which is lyophilized or dried overnight at 105 deg.C and weighed to a content of 17.5%. Treated as impurities.

Polysaccharide compound (P1): filtering the water solution of the active part, performing HP20 column chromatography, washing with water for two column volumes, evaporating the water washing solution to dryness, drying at 105 ℃ overnight, and weighing to obtain the content of 47.9%.

Polyphenol compounds (tannins): and (3) eluting the washed HP20 column with 70% ethanol to light color, evaporating the ethanol washing liquid to dryness to obtain a reddish brown solid, and weighing to obtain the content of 30.5%.

Wherein characteristic peaks of P1, Casuarinin, Gemin A, BETA-ellagitannin and ellagic acid are shown in figure 1.

Wherein, the instruments, reagents and parameters adopted by the reversed phase chromatography are set as follows:

automatic sample injector: waters 2767Sample manager; a pump: waters 2545Binary GradientModule; an ultraviolet detector: waters 2998Photodiode Array Detector; mass spectrometry: waters 3100 MassDetector.

Reagent: acetonitrile, chromatographically pure fisher batch number: 133472, respectively; pure water: milli Q;

liquid phase conditions: mobile phase, a: pure water, B is acetonitrile; flow rate: 0.4 ml/min; sample introduction amount: 5L; column temperature: 35 ℃; a chromatographic column: uniformity C182.8 μm, 3.0x 50mm Column, ACCHROM;

the gradient elution procedure is as follows in table 1:

TABLE 1

Time/min	Mobile phase A (%)	Mobile phase B (%)
			0	100	0
2	100	0
			6	70	30
7	70	30
			7.01	100	0
10	100	0

Mass spectrum conditions:

MODE：ESI+/ESI-，full scan；

Capillary：3.2KV；

Source Temperature：120℃；

Desolvation Temperature：350℃；

Desolvation Gas Flow：600L/Hr；

Cone Gas Flow：50L/Hr；

Cone voltage：30V；

Mass(m/z)：85-2000；

sample preparation: mu.L of the aqueous solution of the extract of Bluebuna obtained in example 3 was directly subjected to sample injection analysis.

Secondly, exploring the effect of the aleppocampus japonicus extract on fibroblasts and colonic epithelial cells:

the positive extract of blue-cloth obtained in example 3 above was evaluated for its specific fibroblast-inhibiting effect by isolating Kunming mouse tail fibroblasts for culture and using human umbilical vein endothelial cells (hUVEC) and muscle satellite cells (C2C12) as non-fibroblast control cells. Specifically, the tissue of Kunming mouse tail is cut into pieces, washed with Phosphate Buffered Saline (PBS) containing antibiotics (100U/mL penicillin, 100mg/mL streptomycin), and added to a culture containing 0.1% trypsin and 0.1% collagenaseThe cells were cultured at 36 ℃ for 20 minutes in nutrient solution, and then the cells suspended in the culture solution were pelleted by centrifugation, and then the pelleted cells were resuspended in DMEM culture solution containing 10% calf serum (FCS) and antibiotics (100U/mL penicillin, 100mg/mL streptomycin). The suspended cells were then plated in 24-well culture plates in a 37 ℃ incubator with 5% CO₂Culture under 95% air. After 2h incubation, the suspended cells were discarded and adherent cells were cultured in DMEM medium containing 10% FCS for two further days. The cultured cells were then washed with PBS, the cells digested with enzyme (0.25% trypsin) were collected, centrifuged, and the cell pellet was resuspended in DMEM medium containing 10% FCS at a cell concentration of 10⁵Cells/ml.

In addition, in order to demonstrate the effect of the euglena extract on colon epithelial cells, SD newborn mouse normal colon epithelial cells were isolated and subjected to experiments. Specifically, colon tissues of postnatal 3-day old pups were taken out, minced, and sufficiently washed with PBS containing antibiotics (100U/mL penicillin, 100mg/mL streptomycin) (at least 5 times) to be added to a culture solution containing 0.1% collagenase type I, IV and hyaluronidase in high-glucose DMEM medium, 10% fetal calf serum, 20mg EGF/liter, and cultured at 37 ℃ for 30 minutes. After digestion, the tube was vigorously pipetted for 5 minutes, transferred to a 25mL sterile centrifuge tube, allowed to stand at room temperature for 1 minute, and the supernatant carefully transferred to another centrifuge tube and the procedure repeated 3 times. Then 10mL of the culture broth was added to the collected supernatant and slowly centrifuged (500rpm) for 2 minutes. The supernatant was discarded. The pellet was added to 10mL of medium and spun at the same speed for 3 minutes, and the procedure was repeated 5 times. The supernatant fraction is predominantly individual colonic epithelial cells and cell debris, and the pellet fraction is predominantly pieces of digested colonic mucosal tissue. The latter was resuspended in the appropriate amount of medium, and the resuspended cells were then placed in a 6-well plate petri dish at 37 ℃ with 5% CO₂Culture in 95% air incubator, change liquid every two days. The cells can adhere to the wall after being inoculated for 3-5 hours, and a monolayer adherent cell layer can be formed after 6-7 days. The cell identification is carried out by using a monoclonal antibody CK-19 cellular immunochemical method. Adherent monolayer-forming cells the cultured cells were washed with PBS,the cells digested with enzyme (0.25% trypsin) were collected, centrifuged, and the cell pellet was resuspended in DMEM medium containing 10% FCS at a cell concentration of 10⁵Cells/ml.

Then, the separated fibroblasts and colonic epithelial cells were seeded in a 96-well plate, and the cultured cells were treated with a medium containing the blue-green extract obtained in example 3 at different gradient concentrations (5 to 100. mu.g/ml medium, blue-green extract dissolved in 5% DMSO). In addition, uvec) and C2C12 cells in parallel were treated with positive extract of blue cloth at the same concentration gradient. The results show that the alexandrium tabacum extract can inhibit the growth rate of cultured fibroblasts in a dose-dependent manner, and the cultured fibroblasts hardly grow when the concentration of active sites in the culture medium reaches 100 mu g/ml. In contrast, no growth inhibition was observed and growth-promoting effects were observed on cultured colonic epithelial cells, HUVEC and C2C12 cells at the same concentration of active sites. It shows that the aleppocampus japonicus extract has specific inhibition effect on the growth of fibroblasts, and has growth promoting effect on colon epithelial cells, vascular endothelial cells and muscle cells. These results suggest that the extract of Geranium hybridum may slow or inhibit the progression of fibrosis in colonic ulcers and promote wound healing.

Thirdly, the clinical cases of treating ulcerative colitis by using the aleppo avens extract are as follows:

the clinical patients of 12 patients showed abdominal pain, tenesmus, frequent bloody diarrhea, weight loss and anemia. Most of the abdominal examinations have tenderness in the colon, and the perianal skin has redness, bruising and perianal inflammation. As a result of 8 cases of patients in colonoscopy, the rectum and sigmoid colon of the patient are suffered from mucosal congestion, edema, fragility, easy bleeding and multiple superficial ulcer of the mucosa. The lesions mostly start from the rectum and are distributed diffusely; the mucosa is rough and fine granular, and forms elliptical superficial ulcers along the longitudinal axis of the intestine, and some are fused into larger irregular ulcers. The mucosa is fragile and easy to bleed, and in 3 cases, pseudopolyp formation is seen, the colon pouch disappears, the intestinal wall is thickened, and the rectum and sigmoid colon cavity are obviously reduced.

Focal biopsies are mainly characterized by chronic inflammatory manifestations. Lesions are mainly concentrated in mucosal layer or submucosa, edema and fibrosis under mucosal membrane. Inflammatory cell infiltration, intestinal gland disorder, destruction, atrophy, basement membrane rupture, disappearance. Laboratory examination finds that feces are purulent and bloody stool most commonly, and a large amount of red blood cells, purulent cells and multinucleated macrophages are detected under a microscope. Immunological examination revealed immune complexes of IgG, IgM, complement and fibrinogen deposition within the ulcerated colonic mucosa. The condition can be alleviated by treatment with adrenocortical hormone and immunosuppressive drugs. According to clinical symptoms, colonoscopy and laboratory examinations, 8 of the patients were diagnosed with ulcerative colitis.

Clystering the 6 patients with ulcerative colitis using a saline solution containing 10% of the upright extract of blue-cloth of example 3 as a test group; the other 2 patients with ulcerative colitis were treated by enema with normal saline as a control group; retention of enema for one hour (2 times/day) is performed on both test group and control group, and the treatment course is one month.

After one week of enema treatment, the clinical symptoms of 6 patients in the test group, such as abdominal pain, tenesmus, frequent bloody diarrhea, etc. were significantly reduced and the body weight was also recovered. In contrast, 2 patients in the control group did not show any signs of improvement.

After one month of treatment, the clinical symptoms (including abdominal pain, tenesmus, frequent bloody diarrhea) of 6 patients in the test group were almost completely disappeared and were almost recovered to normal; colonoscopy found that mucosal congestion and edema in the rectum and sigmoid colon were significantly improved in all patients, with multiple superficial ulcers healing essentially all; the general state of the patient is obviously improved, and the body weight is also increased. While 2 patients in the control group did not substantially have any significant improvement. In addition, after 2 patients in the control group were treated for one month by the same treatment method as that in the test group, clinical symptoms and general conditions of the 2 patients, colonoscopy, were significantly improved.

Fourthly, the clinical cases of the eupatorium lancifolium extract on treating the rheumatoid arthritis are as follows:

clinical patients 8, the patient states first a morning stiffness, in the morning a symmetrical single to multiple joint inflexibility was found, and after moderate activities the morning stiffness was significantly reduced or eliminated. The affected joint has wandering pain, tenderness, swelling and partially restricted mobility. The symptoms of cold such as asthenia, fatigue and fever are reported by 5 patients. Deformities of the knuckles, and rheumatoid nodules were seen in 4 patients. Laboratory examination shows that the rheumatoid factor of the patient is high, the synovial fluid extracted from the damaged joint is turbid and sterile in the synovial fluid examination, and no crystal exists in the synovial fluid examination. Subcutaneous nodules were found in 3 patients, mostly seen in the articular processes, tough in texture and without obvious tenderness. X-ray examination shows that soft tissues around the affected joint swell, the shadow of the joint capsule increases, the joint gap narrows, and the bone around the affected joint is osteoporotic. The patients are treated by anti-inflammatory and external application of traditional Chinese medicines for controlling pain, even hormone and the like, but the treatment effect is not obvious.

3g of the extract of Echinops tabacum obtained in example 3 was orally administered to 6 patients with rheumatoid arthritis as a test group; the other 2 rheumatoid arthritis patients were treated with daily oral placebo as a control group; both the test group and the control group were treated continuously for 6 months.

After 2 months of treatment, the clinical symptoms (such as morning stiffness, joint pain, limited mobility, joint swelling, etc.) were significantly reduced in the 6 patients in the test group. In contrast, 2 patients in the control group did not show any signs of improvement.

After 6 months of treatment, the clinical symptoms of 6 patients in the test group were further reduced, and the normal sensation was substantially restored. Laboratory examination finds that rheumatoid factors of patients are remarkably reduced, joint fluid extracted from damaged joints is normal and sterile after joint fluid examination, and the viscosity of the joint fluid is also normal. X-ray examination revealed that the swollen soft tissue around the affected joint disappeared, the joint capsule was shaded normal size, and the bone density around the affected joint was significantly increased. In contrast, the symptoms of the control group of 2 patients were not significantly improved.

In light of the foregoing description of the preferred embodiment of the present invention, many modifications and variations will be apparent to those skilled in the art without departing from the spirit and scope of the invention. The technical scope of the present invention is not limited to the content of the specification, and must be determined according to the scope of the claims.

Claims

1. The application of the extract of the euonymus japonicus selenka in preparing the medicine for preventing and treating the autoimmune diseases is characterized in that the active ingredients of the extract of the euonymus japonicus selenka comprise polysaccharide compounds and tannin compounds; the mass content of the polysaccharide compound is 35-55%, and the mass content of the tannin compound is 20-40%.

2. The use of aleppocampus japonicus selenka extract as claimed in claim 1, for preparing a medicament for preventing and treating an autoimmune disease, wherein the autoimmune disease is one or more of ulcerative colitis, Crohn's disease, bacillary dysentery, proctitis, enteritis, gastric ulcer and rheumatoid arthritis.

3. Use of a aleppocampus japonicus extract as claimed in claim 2 for preparing a medicament for preventing and treating an autoimmune disease, wherein the autoimmune disease is ulcerative colitis and/or rheumatoid arthritis.

4. The use of the extract of Geum japonicum Thunb for preparing a medicament for preventing and treating autoimmune diseases according to claim 1, wherein the preparation method of the extract of Geum japonicum Thunb comprises the following steps:

5. The application of the extract of aleppocampus japonicus selenka as claimed in claim 4 in the preparation of the medicine for preventing and treating autoimmune diseases, wherein in the step of extracting the aleppocampus selenka by soaking in the first alcohol, and then adding water to continue the soaking extraction to obtain the alcohol extract, the mass volume ratio of the aleppocampus selenka to the first alcohol is (2-4) in kg/L; the volume ratio of the first alcohol to the water is 1 (0.5-1.5).

6. The use of the extract of Geranium hybridum of claim 4 for preparing a medicament for preventing and treating autoimmune diseases, wherein the first alcohol and the second alcohol are each independently C1-C4 alcohols.

7. The use of the extract of aleppo avens as claimed in claim 6 for the preparation of a medicament for the prevention and treatment of autoimmune diseases, wherein the first alcohol is ethanol; the second alcohol is n-butanol.

8. The application of the aleppo avens nakai extract in the preparation of the medicine for preventing and treating autoimmune diseases according to claim 4 is characterized in that the step of concentrating the alcohol extract under reduced pressure and then spray-drying the alcohol extract to obtain solid powder is carried out, wherein the temperature of the concentration under reduced pressure is 40-60 ℃.

9. The application of the extract of radix cynanchi bungei in preparing the medicine for preventing and treating the autoimmune disease according to claim 4 is characterized in that in the step of obtaining the extract of the radix cynanchi bungei, the temperature of the reduced pressure drying treatment is 40-60 ℃ after the alcohol extract is subjected to the reduced pressure drying treatment and then the freeze drying treatment and the grinding treatment are sequentially performed.

10. The application of the extract of radix cynanchi bungei in preparing the medicine for preventing and treating autoimmune diseases according to claim 4 or 9, characterized in that the temperature of the freeze-drying treatment is-80 to-70 ℃ in the step of obtaining the extract of the radix cynanchi bungei by carrying out the reduced pressure drying treatment on the alcohol extract and then sequentially carrying out the freeze-drying treatment and the grinding treatment.